Experimental investigation of vincristine on chemosensitivity through Stathmin regulation in oral squamous cell carcinoma

doi:10.19439/j.sjos.2022.01.001

Abstract

Abstract: PURPOSE: Our previous studies have found that Stathmin, a microtubule depolymerizing protein, is a potential biomarker to guide locally advanced oral squamous cell carcinoma (OSCC) induction chemotherapy. This study further explored the regulatory effect of vincristine on Stathmin and its potention as an alternative chemotherapy drug. METHODS: Stathmin overexpressed and knockdown stable cell lines were constructed. Cell proliferation, q-PCR, Western blot, subcutaneous xenograft and other experimental methods were used to value the regulatory effect of vincristine on Stathmin. The differences were statistically analyzed with SPSS 23.0 software package. RESULTS: Vincristine inhibited the expression of Stathmin in OSCC cell lines. The sensitivity to vincristine was increased in Stathmin overexpressed OSCC cell lines. Vincristine had potent anti-tumor effect for OSCC cell line xenografts with higher Stathmin expression. CONCLUSIONS: Vincristine is a potential alternative chemotherapeutic agent for OSCC with higher Stathmin expression.

Key words: Oral squamous cell carcinoma, Microtubule depolymerizing protein, Vincristine, Individualized treatment

CLC Number:

R739.8

TAN Yi-ran, ZHAO Tong-chao, JU Wu-tong, ZHONG Lai-ping. Experimental investigation of vincristine on chemosensitivity through Stathmin regulation in oral squamous cell carcinoma[J]. Shanghai Journal of Stomatology, 2022, 31(1): 1-5.

References

[1] Zhong LP, Zhang ZY.Reply to K. Devisetty et al[J]. J Clin Oncol, 2013, 31(23): 2972-2973.
[2] Zhong LP, Zhang CP, Ren GX, et al.Randomized phase Ⅲ trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma[J]. J Clin Oncol, 2013, 31(6): 744-751.
[3] Niethammer P, Bastiaens P, Karsenti E.Stathmin-tubulin interaction gradients in motile and mitotic cells[J]. Science, 2004, 303(5665): 1862-1866.
[4] Baquero MT, Hanna JA, Neumeister V, et al.Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer[J]. Cancer, 2012, 118(19): 4660-4669.
[5] Nie W, Xu MD, Gan L, et al.Overexpression of stathmin 1 is a poor prognostic biomarker in non-small cell lung cancer[J]. Lab Invest, 2015, 95(1): 56-64.
[6] Biaoxue R, Xiguang C, Hua L, et al.Stathmin-dependent molecular targeting therapy for malignant tumor: the latest 5 years' discoveries and developments[J]. J Transl Med, 2016, 14(1): 279-297.
[7] Johnsson A, Zeelenberg I, Min Y, et al.Identification of genes differentially expressed in association with acquired cisplatin resistance[J]. Br J Cancer, 2000, 83(8): 1047-1054.
[8] Lin X, Liao Y, Xie J, et al.Op18/stathmin is involved in the resistance of taxol among different epithelial carcinoma cell lines[J]. Cancer Biother Radiopharm, 2014, 29(9): 376-386.
[9] Ju WT, Ma HL, Zhao TC, et al.Stathmin guides personalized therapy in oral squamous cell carcinoma[J]. Cancer Sci, 2020, 111(4): 1303-1313.
[10] Bai S, Zhang BY, Dong Y.Impact of taxanes on androgen receptor signaling[J]. Asian J Androl, 2019, 21(3): 249-252.
[11] Florian S, Mitchison TJ.Anti-microtubule drugs[J]. Methods Mol Biol, 2016,1413: 403-421.
[12] Nishio K, Nakamura T, Koh Y, et al.Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells[J]. Cancer, 2001, 91(8): 1494-1499.
[13] Takahashi M, Yang XJ, Lavery TT, et al.Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features[J]. Cancer Res, 2002, 62(22): 6598-6605.
[14] Gleeson M, Peckitt C, To YM, et al.CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymp-homa(CHEMO-T): a phase 2, multicentre, randomised, open-label trial[J]. Lancet Haematol, 2018, 5(5): e190-e200.
[15] Watanabe T, Tobinai K, Wakabayashi M, et al.Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial[J]. Lancet Haematol, 2018, 5(11): e520-e531.
[16] Luo Z, Zhang X, Peng W, et al.A phase Ⅱ study of gemcitabine, vincristine, and cisplatin as second-line treatment for patients with advanced soft tissue sarcoma[J]. Medicine (Baltimore), 2015, 94(43): e1777-e1782.
[17] Li WP, Liu H, Chen L, et al.A clinical comparison of lobaplatin or cisplatin with mitomycine and vincristine in treating patients with cervical squamous carcinoma[J]. Asian Pac J Cancer Prev, 2015, 16(11): 4629-4631.
[18] Tokunaga H, Nagase S, Yoshinaga K, et al.Small cell carcinoma of the uterine cervix: clinical outcome of concurrent chemoradiotherapy with a multidrug regimen[J]. Tohoku J Exp Med, 2013, 229(1): 75-81.
[19] Verrills NM, Liem NL, Liaw TY, et al.Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia-an in vivo study[J]. Proteomics, 2006, 6(5): 1681-1694.